ANTX Stock Summary and Trading Ideas (An2 Therapeutics | NASDAQ:ANTX)

AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.

An2 Therapeutics trades on the NASDAQ stock market under the symbol ANTX.

As of April 2, 2026, ANTX stock price declined to $3.41 with 29,568 million shares trading.

ANTX has a beta of -0.25, meaning it tends to be less sensitive to market movements. ANTX has a correlation of 0.00 to the broad based SPY ETF.

ANTX has a market cap of $122.56 million. This is considered a Micro Cap stock.

In the last 3 years, ANTX traded as high as $22.22 and as low as $.87.

The top ETF exchange traded funds that ANTX belongs to (by Net Assets): VTI, VXF, IWC, DFAS, DFMC.

ANTX has outperformed the market in the last year with a return of +147.1%, while the SPY ETF gained +17.8%. In the last 3 month period, ANTX beat the market returning +199.1%, while SPY returned -3.9%. However, in the most recent 2 weeks ANTX has underperformed the stock market by returning -26.2%, while SPY returned -0.9%.

ANTX support price is $3.13 and resistance is $3.77 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANTX shares will trade within this expected range on the day.